TERMS & CONDITIONS | SpotitEarly

top of page

PRODUCTS
- CANCER PRE-SCREENING
- BRCA GERMLINE
TECH & SCIENCE
CLINICAL TRIALS
ABOUT
LET'S CONNECT

BIO-SENSORS
BIO-HYBRID PLATFORM
CANCER PRE-SCREENING
BRCA GERMLINE
CLINICAL TRIALS
OUR STORY
TEAM ַַַַַַַַַַַַַ& INVESTORS
LET'S CONNECT

ALL RIGHTS RESERVED,
SPOTITEARLY 2024

TERMS & CONDITIONS

PRIVACY POLICY

CLIA registration: 99D2307137

USPTO patent pending: WO2023239834A1

hello@SpotitEarly.com

BACK TO TOP

SpotitEarly tests are not intended to replace current screening procedures, but rather to be used as an additional pre-screening layer to complement preventative protocols already in place.

The SpotitEarly tests have not been approved by the Food and Drug Administration (FDA) and are currently under development and validation.

PRODUCTS
- CANCER PRE-SCREENING
- BRCA GERMLINE
TECH & SCIENCE
CLINICAL TRIALS
ABOUT
LET'S CONNECT

bottom of page